JP2023550740A5 - - Google Patents

Info

Publication number
JP2023550740A5
JP2023550740A5 JP2023529980A JP2023529980A JP2023550740A5 JP 2023550740 A5 JP2023550740 A5 JP 2023550740A5 JP 2023529980 A JP2023529980 A JP 2023529980A JP 2023529980 A JP2023529980 A JP 2023529980A JP 2023550740 A5 JP2023550740 A5 JP 2023550740A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
cancer
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023529980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550740A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/060679 external-priority patent/WO2022107027A1/en
Publication of JP2023550740A publication Critical patent/JP2023550740A/ja
Publication of JP2023550740A5 publication Critical patent/JP2023550740A5/ja
Pending legal-status Critical Current

Links

JP2023529980A 2020-11-18 2021-11-18 Ｓｔｉｎｇアゴニスト、チェックポイント阻害剤、及び放射線の投与 Pending JP2023550740A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063115398P 2020-11-18 2020-11-18
US63/115,398 2020-11-18
US202163140125P 2021-01-21 2021-01-21
US63/140,125 2021-01-21
US202163184295P 2021-05-05 2021-05-05
US63/184,295 2021-05-05
US202163275480P 2021-11-04 2021-11-04
US63/275,480 2021-11-04
PCT/IB2021/060679 WO2022107027A1 (en) 2020-11-18 2021-11-18 Administration of sting agonist, checkpoint inhibitors, and radiation

Publications (2)

Publication Number Publication Date
JP2023550740A JP2023550740A (ja) 2023-12-05
JP2023550740A5 true JP2023550740A5 (enExample) 2024-11-26

Family

ID=79287967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023529980A Pending JP2023550740A (ja) 2020-11-18 2021-11-18 Ｓｔｉｎｇアゴニスト、チェックポイント阻害剤、及び放射線の投与

Country Status (9)

Country Link
US (1) US20240335464A1 (enExample)
EP (1) EP4247385B1 (enExample)
JP (1) JP2023550740A (enExample)
KR (1) KR20230110254A (enExample)
AU (1) AU2021383424A1 (enExample)
CA (1) CA3196529A1 (enExample)
MX (1) MX2023005695A (enExample)
TW (1) TW202233206A (enExample)
WO (1) WO2022107027A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026053158A1 (en) * 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of neuroendocrine neoplasms
WO2026053159A1 (en) * 2024-09-06 2026-03-12 Takeda Pharmaceutical Company Limited Dazostinag or conjugates thereof for treatment of adenoid cystic carcinomas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
WO2018100558A2 (en) 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
AU2018311965A1 (en) * 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
WO2020049534A1 (en) * 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
TWI925817B (zh) * 2019-05-10 2026-05-21 日商武田藥品工業股份有限公司 抗體藥物結合物
EP3996718A1 (en) * 2019-07-09 2022-05-18 Takeda Pharmaceutical Company Limited Administration of sting agonist and checkpoint inhibitors

Similar Documents

Publication Publication Date Title
Biau et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma
JP2019532051A5 (enExample)
ES2870805T3 (es) Tratamiento combinado de cáncer
JP2018508516A5 (enExample)
JP2021512121A5 (enExample)
CN105452258B (zh) 使用双核金(i)化合物用于癌症治疗的方法
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
Haddad et al. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
ES2688809T3 (es) Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
JP2023102786A5 (enExample)
JP2021511344A5 (enExample)
Kim et al. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer
FI3888647T3 (fi) Ezh1/2-kaksoisestäjän sisältävä farmaseuttinen koostumus käytettäväksi yhdistelmälääkkeenä
JP2014512362A5 (enExample)
JP2023531090A5 (enExample)
JP6449537B2 (ja) 抗腫瘍剤、及び、抗腫瘍用キット
JP2022520981A (ja) 経口投与されるジオキソランヌクレオチドを抗ｐｄ１又は抗ｐｄｌ１モノクローナル抗体と組み合わせて用いる肝臓がんの治療法
Mortimer et al. Safety considerations for use of bone-targeted agents in patients with cancer
RU2005132175A (ru) Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию
JP2024520307A5 (enExample)
TW202143973A (zh) 用於治療ＰＲＣ２介導的疾病或障礙的Ｎ—（（５—氟—２，３—二氫苯并呋喃—４—基）甲基）—８—（２—甲基吡啶—３—基）—［１，２，４］三唑并［４，３—ｃ］嘧啶—５—胺或其藥學上可接受的鹽之給藥方案
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
AU2022408062B2 (en) Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor